Sarepta Therapeutics, Inc. - Common Stock (SRPT)

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Piper Sandler cut its Elevidys peak sales estimate to $1.7 billion from $2.4 billion.

The company is working with an independent group to determine if there's a better immunosuppressive regimen.

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

While Dow Jones futures gained 0.41% at the time of writing, the S&P 500 futures rose 0.48%.

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

BMO Capital downgraded the stock, warning of rising regulatory uncertainty and potential revenue impact.

RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch.

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 per share was significantly below analysts’ consensus estimates.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 7.5%. This drop was discouraging since the S&P 500 held steady.

These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and next

Roche's APHINITY study shows promising results for HER2-positive breast cancer treatment with Perjeta regime

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta Therapeutics (NASDAQ:SRPT).